IceCure's ProSense Set to Revolutionize Tumor Treatment with Groundbreaking Cryoablation Data at CIRSE 2025

The medical world is buzzing with anticipation as IceCure Medical Ltd. (NASDAQ: ICCM), a trailblazer in liquid nitrogen-based cryoablation, prepares to make a significant impact at the upcoming Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2025 Annual Meeting. Slated for September 13-17, 2025, in the vibrant city of Berlin, Germany, this prestigious event will serve as a pivotal platform for IceCure's innovative ProSense™ System to showcase its remarkable capabilities in the minimally invasive treatment of diverse tumors.

At the forefront of these exciting developments will be Dr.

Gabriel Rabinovich, the visionary CEO of IceCure, who is scheduled to present compelling clinical data. These presentations will underscore the exceptional efficacy and safety profile of cryoablation utilizing the ProSense™ System for both benign and malignant tumors. This highly anticipated session is expected to draw considerable attention from leading interventional radiologists and medical professionals eager to explore the next generation of cancer treatment.

IceCure's presence at CIRSE 2025 will shine a spotlight on a comprehensive array of published results across various critical indications.

Among the highlights will be the profound insights into the treatment of kidney and bone tumors, areas where traditional approaches can be highly invasive. Furthermore, the meeting will feature crucial findings from a multi-center study dedicated to the treatment of lung tumors, addressing a particularly challenging disease.

Patients suffering from breast fibroadenomas will also find new hope with the presentation of data from a prospective study demonstrating ProSense’s gentle yet effective approach.

What makes the ProSense™ System so revolutionary? At its core, ProSense employs cryoablation, a sophisticated technique that uses extreme cold to precisely destroy target tissues without the need for traditional surgery.

Liquid nitrogen circulates through tiny needles, creating an ice ball that engulfs and eradicates tumor cells while sparing surrounding healthy tissue. This minimally invasive approach translates into numerous benefits for patients: significantly reduced pain, shorter recovery times, and often, the preservation of organ function that might be compromised by conventional surgical resections.

It offers a crucial alternative for patients who are not candidates for surgery or prefer a less invasive option.

IceCure's commitment to advancing patient care and pushing the boundaries of medical technology is evident in these forthcoming presentations. By providing evidence-based data on ProSense’s ability to treat a wide spectrum of tumors effectively and safely, the company is solidifying its position as a leader in the field of interventional oncology.

CIRSE 2025 will not just be a meeting; it will be a testament to the future of cancer treatment – a future that is less invasive, more precise, and ultimately, more hopeful for countless patients worldwide.